In this edition, foslevodopa-foscarbidopa improves motor symptoms in advanced PD, posterior surgery for treating cervical radiculopathy, Tysabri favored over IV in patients with relapsing-remitting MS and more. Read the full coverage here: Continuous subcutaneous foslevodopa-foscarbidopa improves motor symptoms in advanced PD Posterior surgery noninferior to anterior for treating cervical radiculopathy Subcutaneous delivery of Tysabri favored over IV in patients with relapsing-remitting MS NeuroLogica receives FDA clearance for multiuse imaging tool Vumerity effective over 96 weeks in patients with relapsing-remitting MS References: Broekema AEH, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.4208. Gold R, et al. SISTER – subcutaneous: non-interventional, observational, prospective, German multicenter, open-label study over 12-months for Tysabri patient preference – experience from real world – preliminary results of the 1st interim analysis. Presented at: ECTRIMS 2022; Oct. 26-28; Amsterdam. Press Release Singer BA, et al. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Presented at: ECTRIMS 2022; Oct. 26-28; Amsterdam. Soileau MJ, et al. Lancet Neurol. 2022;doi:10.1016/S1474-4422(22)00400-8.

Ver todos los episodios